Company intelligence / Profile preview

BW Therapeutics

Tampa, Florida, United States

Ownership: Private
Employees: ~1
Development stage: Other

Overview

BW Therapeutics was a private U.S. biotechnology company based in Tampa, Florida, focused on oncology drug development. The company was founded in 2019 and centered its pipeline on TYN-21, described as a proprietary 505(b)(2) formulation of paclitaxel intended to provide equivalency to Abraxane. Publicly available information suggests BW Therapeutics pursued a relatively narrow, single-asset strategy and was seeking Series A financing and strategic partnering in early 2020. Company databases now list the business as closed, with no evidence of an approved product or active late-stage clinical pipeline.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

TYN-21

Unknown

Beyond the preview

Go deeper on BW Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BW Therapeutics.

Explore the full profile